NCT03462459View on ClinicalTrials.gov

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

July 6, 2023

Study Completion Date

July 6, 2023

Conditions
Recurrent Clostridium Difficile InfectionClostridium Difficile InfectionCDIC.Difficile DiarrheaC. Diff ColitisC.Difficile Colitis
Interventions
DRUG

Vancomycin

Vancomycin capsule, 125 mg

DRUG

Placebo

Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule

Trial Locations (2)

53226

Medical College of Wisconsin, Milwaukee

53705

University of Wisconsin-Madison, Madison

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Medical College of Wisconsin

OTHER

collaborator

Agency for Healthcare Research and Quality (AHRQ)

FED

collaborator

Henry Ford Hospital

OTHER

collaborator

Mayo Clinic

OTHER

lead

University of Wisconsin, Madison

OTHER

NCT03462459 - Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection | Biotech Hunter | Biotech Hunter